<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="telo-20260630.xsd#Cover" roleURI="http://telomirpharma.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20260630.xsd#BalanceSheets" roleURI="http://telomirpharma.com/role/BalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20260630.xsd#BalanceSheetsParenthetical" roleURI="http://telomirpharma.com/role/BalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20260630.xsd#StatementsOfOperations" roleURI="http://telomirpharma.com/role/StatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20260630.xsd#StatementsOfChangesInStockholdersEquityDeficit" roleURI="http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquityDeficit" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20260630.xsd#StatementsOfCashFlows" roleURI="http://telomirpharma.com/role/StatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20260630.xsd#DescriptionOfBusiness" roleURI="http://telomirpharma.com/role/DescriptionOfBusiness" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20260630.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://telomirpharma.com/role/SummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20260630.xsd#PrepaidExpenses" roleURI="http://telomirpharma.com/role/PrepaidExpenses" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20260630.xsd#FairValueMeasurements" roleURI="http://telomirpharma.com/role/FairValueMeasurements" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20260630.xsd#RelatedPartyAssetAcquisitionOfTeli" roleURI="http://telomirpharma.com/role/RelatedPartyAssetAcquisitionOfTeli" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20260630.xsd#LicenseAgreementRelatedParty" roleURI="http://telomirpharma.com/role/LicenseAgreementRelatedParty" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20260630.xsd#RelatedPartiesBalancesAndTransactions" roleURI="http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactions" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20260630.xsd#InsuranceLoanPayable" roleURI="http://telomirpharma.com/role/InsuranceLoanPayable" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20260630.xsd#CommitmentsAndContingencies" roleURI="http://telomirpharma.com/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20260630.xsd#StockholdersEquity" roleURI="http://telomirpharma.com/role/StockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20260630.xsd#SegmentInformation" roleURI="http://telomirpharma.com/role/SegmentInformation" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20260630.xsd#SubsequentEvents" roleURI="http://telomirpharma.com/role/SubsequentEvents" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20260630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://telomirpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20260630.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://telomirpharma.com/role/SummaryOfSignificantAccountingPoliciesTables" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20260630.xsd#PrepaidExpensesTables" roleURI="http://telomirpharma.com/role/PrepaidExpensesTables" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20260630.xsd#FairValueMeasurementsTables" roleURI="http://telomirpharma.com/role/FairValueMeasurementsTables" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20260630.xsd#StockholdersEquityTables" roleURI="http://telomirpharma.com/role/StockholdersEquityTables" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20260630.xsd#SegmentInformationTables" roleURI="http://telomirpharma.com/role/SegmentInformationTables" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20260630.xsd#DescriptionOfBusinessDetailsNarrative" roleURI="http://telomirpharma.com/role/DescriptionOfBusinessDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20260630.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://telomirpharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20260630.xsd#ScheduleOfCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShareDetails" roleURI="http://telomirpharma.com/role/ScheduleOfCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShareDetails" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20260630.xsd#ScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails" roleURI="http://telomirpharma.com/role/ScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20260630.xsd#ScheduleOfFairValueHierarchyOfValuationInputsDetails" roleURI="http://telomirpharma.com/role/ScheduleOfFairValueHierarchyOfValuationInputsDetails" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20260630.xsd#RelatedPartyAssetAcquisitionOfTeliDetailsNarrative" roleURI="http://telomirpharma.com/role/RelatedPartyAssetAcquisitionOfTeliDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20260630.xsd#LicenseAgreementRelatedPartyDetailsNarrative" roleURI="http://telomirpharma.com/role/LicenseAgreementRelatedPartyDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20260630.xsd#RelatedPartiesBalancesAndTransactionsDetailsNarrative" roleURI="http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20260630.xsd#InsuranceLoanPayableDetailsNarrative" roleURI="http://telomirpharma.com/role/InsuranceLoanPayableDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20260630.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://telomirpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20260630.xsd#ScheduleOfWarrantActivityDetails" roleURI="http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20260630.xsd#ScheduleOfStockOptionActivityDetails" roleURI="http://telomirpharma.com/role/ScheduleOfStockOptionActivityDetails" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20260630.xsd#StockholdersEquityDetailsNarrative" roleURI="http://telomirpharma.com/role/StockholdersEquityDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20260630.xsd#ScheduleOfSegmentInformationDetails" roleURI="http://telomirpharma.com/role/ScheduleOfSegmentInformationDetails" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20260630.xsd#SegmentInformationDetailsNarrative" roleURI="http://telomirpharma.com/role/SegmentInformationDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="telo-20260630.xsd#SubsequentEventsDetailsNarrative" roleURI="http://telomirpharma.com/role/SubsequentEventsDetailsNarrative" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedBonusesCurrentAndNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedBonusesCurrentAndNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LoansPayableCurrent" xlink:label="loc_us-gaapLoansPayableCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapLoansPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaapInterestExpenseNonoperating" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpenseNonoperating" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/StatementsOfChangesInStockholdersEquityDeficit" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders&apos; Equity (Deficit) (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="telo-20260630.xsd#TELO_StockbasedCompensationExpenseStockOptionModification" xlink:label="loc_TELOStockbasedCompensationExpenseStockOptionModification" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_TELOStockbasedCompensationExpenseStockOptionModification" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="telo-20260630.xsd#TELO_IncreaseDecreaseInAccruedCompensation" xlink:label="loc_TELOIncreaseDecreaseInAccruedCompensation" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_TELOIncreaseDecreaseInAccruedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="telo-20260630.xsd#TELO_ProceedsFromRepaymentsOfOfficer" xlink:label="loc_TELOProceedsFromRepaymentsOfOfficer" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_TELOProceedsFromRepaymentsOfOfficer" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="telo-20260630.xsd#TELO_ProceedsFromIssuanceOfInsuranceLoanPayable" xlink:label="loc_TELOProceedsFromIssuanceOfInsuranceLoanPayable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_TELOProceedsFromIssuanceOfInsuranceLoanPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="telo-20260630.xsd#TELO_RepaymentsOnInsuranceLoanPayable" xlink:label="loc_TELORepaymentsOnInsuranceLoanPayable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_TELORepaymentsOnInsuranceLoanPayable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="telo-20260630.xsd#TELO_NetProceedsFromSaleOfCommonStockInAtm" xlink:label="loc_TELONetProceedsFromSaleOfCommonStockInAtm" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_TELONetProceedsFromSaleOfCommonStockInAtm" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/DescriptionOfBusiness" xlink:title="999007 - Disclosure - Description of business" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999008 - Disclosure - Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/PrepaidExpenses" xlink:title="999009 - Disclosure - Prepaid expenses" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/FairValueMeasurements" xlink:title="999010 - Disclosure - Fair value measurements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/RelatedPartyAssetAcquisitionOfTeli" xlink:title="999011 - Disclosure - Related Party Asset Acquisition of TELI" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/LicenseAgreementRelatedParty" xlink:title="999012 - Disclosure - License agreement, related party" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactions" xlink:title="999013 - Disclosure - Related parties&#8217; balances and transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/InsuranceLoanPayable" xlink:title="999014 - Disclosure - Insurance loan payable" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/CommitmentsAndContingencies" xlink:title="999015 - Disclosure - Commitments and contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/StockholdersEquity" xlink:title="999016 - Disclosure - Stockholders&#8217; equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/SegmentInformation" xlink:title="999017 - Disclosure - Segment Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/SubsequentEvents" xlink:title="999018 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999019 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999020 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/PrepaidExpensesTables" xlink:title="999021 - Disclosure - Prepaid expenses (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/FairValueMeasurementsTables" xlink:title="999022 - Disclosure - Fair value measurements (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/StockholdersEquityTables" xlink:title="999023 - Disclosure - Stockholders&#8217; equity (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/SegmentInformationTables" xlink:title="999024 - Disclosure - Segment Information (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/DescriptionOfBusinessDetailsNarrative" xlink:title="999025 - Disclosure - Description of business (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999026 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfCommonStockEquivalentsWereExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:title="999027 - Disclosure - Schedule of common stock equivalents were excluded from computation of diluted net loss per share (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails" xlink:title="999028 - Disclosure - Schedule of prepaid expense and other current assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseCurrent" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseCurrent" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfFairValueHierarchyOfValuationInputsDetails" xlink:title="999029 - Disclosure - Schedule of fair value hierarchy of the valuation inputs (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/RelatedPartyAssetAcquisitionOfTeliDetailsNarrative" xlink:title="999030 - Disclosure - Related Party Asset Acquisition of TELI (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/LicenseAgreementRelatedPartyDetailsNarrative" xlink:title="999031 - Disclosure - License agreement, related party (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/RelatedPartiesBalancesAndTransactionsDetailsNarrative" xlink:title="999032 - Disclosure - Related parties&#8217; balances and transactions (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/InsuranceLoanPayableDetailsNarrative" xlink:title="999033 - Disclosure - Insurance loan payable (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999034 - Disclosure - Commitments and contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfWarrantActivityDetails" xlink:title="999035 - Disclosure - Schedule of Warrant Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="999036 - Disclosure - Schedule of Stock Option Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/StockholdersEquityDetailsNarrative" xlink:title="999037 - Disclosure - Stockholders&#8217; equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/ScheduleOfSegmentInformationDetails" xlink:title="999038 - Disclosure - Schedule of segment information (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaapInterestExpenseNonoperating" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpenseNonoperating" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/SegmentInformationDetailsNarrative" xlink:title="999039 - Disclosure - Segment Information (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://telomirpharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="999040 - Disclosure - Subsequent Events (Details Narrative)" />
</link:linkbase>
